report
design
synthesi
seri
dipeptidetyp
inhibitor
novel
scaffold
display
potent
inhibitori
activ
sarscov
pro
dock
studi
involv
bind
dipeptid
lead
compound
pro
suggest
modif
structur
flexibl
n
glycin
variou
rigid
moieti
modif
led
identif
sever
potent
deriv
includ
inhibitori
activ
k
ic
submicromolar
nanomolar
rang
compound
particular
display
potent
inhibitori
activ
k
valu
mm
potenc
higher
potenc
lead
compound
k
mm
addit
k
valu
good
agreement
bind
affin
nm
observ
isotherm
titrat
calorimetri
itc
sar
studi
around
group
lead
led
identif
rigid
unit
one
best
moieti
optim
show
methoxi
substitut
indol
unit
highli
favor
enhanc
inhibitori
potenc
sever
acut
respiratori
syndrom
highli
contagi
fatal
respiratori
diseas
infect
individu
die
within
month
emerg
diseas
novemb
earli
extens
collabor
research
cooper
lead
expert
world
health
organ
led
rapid
identif
novel
coronaviru
cov
etiolog
agent
underli
pandem
sar
infect
sar
outbreak
consequ
success
control
begin
reemerg
sarscov
pandem
still
consid
potenti
risk
new
strain
sar
could
potenti
sever
strain
contribut
outbreak
sinc
two
addit
human
coronaviru
identifi
patient
around
world
new
virus
character
found
significantli
less
lethal
sarscov
new
sarslik
viru
hcovemc
recent
identifi
least
two
individu
one
die
first
case
fatal
respiratori
ill
similar
deadli
sar
recent
confirm
britain
possibl
futur
sarslik
pandem
remain
vaccin
antivir
agent
yet
develop
prevent
treat
sarslik
infect
sarscov
encod
chymotrypsinlik
proteas
cl
pro
play
pivot
role
replic
viru
unlik
common
serin
proteas
contain
serhisasp
catalyt
triad
activ
site
sarscov
pro
contain
cysehi
catalyt
dyad
function
analog
porcin
transmiss
gastroenter
viru
main
proteas
human
coronaviru
main
proteas
cy
act
nucleophil
wherea
function
gener
base
sinc
sarscov
pro
play
import
role
viru
life
cycl
recogn
viabl
target
antisar
drug
develop
ongo
effort
led
develop
sever
inhibitor
moder
remark
potenc
sarscov
pro
shown
fig
first
tripeptid
lead
compound
bear
electrophil
keton
warhead
moieti
develop
natur
peptid
sequenc
extens
structur
modif
regard
mechan
action
electrophil
keton
react
activ
site
cyssh
group
result
format
hemithioket
intermedi
enzym
inhibitor
interfer
enzym
function
henc
predict
revers
inhibitor
sarscov
pro
subsequ
sar
studi
afford
promis
inhibitor
excel
inhibitori
activ
k
nm
respect
recent
report
seri
low
molecular
weight
dipeptidetyp
inhibitor
valin
moieti
remov
form
lead
compound
see
fig
studi
led
identif
compound
promis
lead
inhibitori
activ
k
mm
fig
structur
point
view
narylglycyl
moieti
recogn
crucial
activ
amin
function
glycyl
moieti
form
hydrogen
bond
backbon
amino
acid
residu
pro
dock
studi
studi
extend
report
rigidifi
narylglycyl
unit
search
suitabl
motif
favor
conform
would
provid
better
interact
increas
inhibitori
activ
toward
sarscov
pro
accordingli
design
synthes
seri
dipeptidetyp
inhibitor
novel
scaffold
test
inhibitori
activ
compound
sarscov
pro
sever
analog
identifi
exhibit
potent
inhibitori
activ
rel
lead
compound
particular
compound
bear
group
exhibit
excel
inhibitori
activ
k
ic
valu
mm
respect
extens
molecular
dock
studi
compound
conduct
model
bind
interact
inhibitor
synthesi
target
compound
envis
assembl
two
key
fragment
peptid
ctermin
benzothiazol
deriv
scheme
shown
scheme
peptid
intermedi
synthes
via
coupl
reaction
variou
carboxyl
acid
leucin
tertbutyl
ester
follow
deprotect
tertbutyl
group
carboxyl
acid
acid
acid
acid
acid
acid
acid
acid
acid
acid
acid
benzo
acid
acid
acid
acid
commerci
avail
carboxyl
acid
synthes
shown
scheme
briefli
commerci
avail
methyl
underw
odemethyl
presenc
boron
tribromid
bbr
produc
correspond
ester
subsequ
treat
variou
alcohol
mitsunobu
condit
use
diethyl
azodicarboxyl
dead
triphenylphosphin
pph
thf
follow
deprotect
lithium
hydroxid
water
lioh
h
furnish
andor
acid
respect
commerci
avail
acid
ethyl
ester
submit
vilsmeierehaack
formyl
presenc
phosphoryloxi
chlorid
pocl
dmf
produc
hand
acyl
acetyl
chlorid
presenc
anhydr
aluminum
chlorid
alcl
afford
compound
deriv
reduc
presenc
triethyl
silylhydrid
et
sih
furnish
hydrolyz
afford
correspond
acid
respect
synthesi
peptid
fragment
achiev
leucin
tertbutyl
ester
presenc
variou
carboxyl
acid
via
carbodiimid
edc
hobt
mediat
coupl
method
presenc
triethylamin
tea
dmf
nprotect
amino
acid
tertbutyl
ester
subsequ
deprotect
trifluoroacet
acidwat
h
afford
nprotect
amino
acid
use
directli
subsequ
step
treatment
bromoacetonitril
follow
reduct
pto
cycliz
hydrolysi
scheme
coupl
n
odimethylhydroxylamin
via
edcehobt
method
afford
weinreb
amid
weinreb
amid
coupl
benzothiazol
presenc
nbutyl
lithium
nbuli
c
furnish
deprotect
subsequ
coupl
peptid
presenc
obenzotriazolen
n
n
n
tetramethyluroniumhexafluoro
phosphat
hbtu
dipea
dmf
afford
titl
compound
compound
purifi
revers
phase
hplc
biolog
evalu
character
h
nmr
c
nmr
mass
spectrometri
puriti
compound
exceed
k
ic
valu
synthes
compound
sarscov
pro
list
tabl
compound
subject
fluorometr
proteas
inhibitori
assay
use
procedur
similar
mention
earlier
studi
briefli
kinet
paramet
determin
constant
substrat
concentr
inhibitor
concentr
vari
assess
k
valu
ic
valu
determin
certain
potent
inhibitor
base
appar
decreas
substrat
concentr
htsavlqsgfrknh
upon
digest
sarscov
pro
describ
previous
cleavag
reaction
monitor
analyt
hplc
cleavag
rate
calcul
decreas
substrat
peak
area
tabl
report
k
ic
valu
mean
independ
experi
previou
studi
report
seri
low
molecular
weight
dipeptidetyp
sarscov
pro
inhibitor
among
compound
bear
n
glycyl
exhibit
potent
inhibitori
activ
k
valu
mm
studi
envis
substitut
narylglycyl
unit
could
improv
inhibitori
potenc
pro
therefor
design
synthes
seri
analog
bear
rigid
motif
evalu
sarscov
pro
first
attempt
shown
tabl
n
glycyl
unit
replac
dlpyroglutamyl
k
mm
k
mm
rigid
scaffold
inhibitori
activ
result
compound
dramat
reduc
compar
activ
k
mm
hand
introduct
unit
k
mm
ic
mm
yield
higher
inhibitori
potenc
rel
respect
potent
activ
rel
studi
suggest
rigid
introduc
place
moieti
n
glycyl
lead
compound
display
appreci
inhibitori
activ
thu
compound
serv
lead
compound
optim
step
substitu
effect
differ
posit
indol
unit
investig
introduc
wide
varieti
substitu
initi
substitu
introduc
indol
unit
includ
k
mm
ic
mm
k
mm
k
mm
ic
mm
result
suggest
substitu
indol
unit
exhibit
good
inhibitori
potenc
rel
respect
lead
compound
deriv
next
methoxi
group
introduc
indol
unit
shown
activ
lower
activ
thu
substitut
significantli
improv
inhibitori
activ
hand
methoxi
substitut
indol
unit
k
mm
ic
mm
exhibit
excel
inhibitori
activ
increas
activ
rel
respect
deriv
find
reveal
methoxi
substitut
indol
unit
significantli
improv
inhibitori
activ
group
indol
unit
examin
substitut
k
mm
k
mm
ic
mm
k
mm
ic
mm
moieti
howev
inhibitori
activ
lower
activ
deriv
studi
strongli
suggest
optim
methoxi
group
indol
import
isopropoxi
isobutyloxi
hydroxyl
group
test
introduct
substitut
indol
unit
start
lead
compound
k
mm
k
mm
group
introduc
first
howev
inhibitori
activ
sever
reduc
rel
activ
scheme
synthet
outlin
prepar
reagent
condit
hn
ome
hcl
edc
hcl
hobt
h
et
n
dmf
crt
h
ii
benzothiazol
nbuli
thf
crt
h
iii
tfa
ch
cl
crt
h
iv
hbtu
dipea
dmf
crt
h
follow
hplc
purif
note
substitu
r
r
indic
tabl
result
suggest
substitut
indol
unit
fruit
direct
studi
indol
unit
next
examin
vari
heterocycl
replac
benzimidazol
benzothiazol
benzofuran
indolin
scaffold
compound
bear
benzimidazol
k
ic
mm
exhibit
potent
inhibitori
activ
lead
compound
howev
indolin
k
mm
benzothiazol
k
mm
benzofuran
k
mm
lower
activ
lead
compound
compound
bear
benzofuran
unit
display
sever
reduc
inhibitori
potenc
compar
lead
compound
observ
low
activ
attribut
disrupt
hydrogen
bond
interact
posit
result
suggest
hydrogen
bond
properti
amin
moieti
indol
unit
import
achiev
effect
inhibitori
activ
see
fig
posit
carbonyl
substitut
indol
unit
examin
next
inhibitori
activ
deriv
k
mm
bear
reduc
rel
activ
compound
bear
substitut
may
interrupt
hydrogen
bond
interact
proteas
see
fig
result
strongli
suggest
substitut
indol
unit
import
inhibitori
potenc
bind
mode
potent
compound
comput
model
use
threedimension
structur
sarscov
pro
base
report
crystal
structur
procedur
similar
procedur
describ
previous
use
molecular
dock
orang
stick
examin
comparison
lead
compound
blue
stick
structur
similar
tripeptid
ligand
light
blue
stick
dock
structur
elucid
xray
crystallographi
fig
sever
minim
process
perform
use
forc
field
model
solvat
environ
surround
inhibitor
molecular
simul
subsequ
perform
shown
fig
moieti
interact
region
proteas
lead
compound
origin
ligand
heterocycl
unit
mimick
valin
report
substrat
phenyl
ring
indol
unit
partial
occupi
rigid
moieti
unit
appear
occupi
region
activ
site
appropri
volum
conform
favor
conform
structur
flexibl
n
glycyl
moieti
inde
fit
rigid
moieti
may
contribut
higher
inhibitori
potenc
compar
detail
interact
activ
site
shown
fig
hydrogen
bond
amin
moieti
nh
indol
unit
backbon
amino
acid
residu
pro
observ
bond
length
insight
structureeact
relationship
sought
perform
dock
studi
analyz
bind
interact
certain
compound
display
notabl
variat
inhibitori
activ
fig
initi
lead
compound
bear
unit
dock
fig
reveal
hydrogen
bond
interact
similar
predict
fig
howev
bear
moieti
could
form
hydrogen
bond
interact
backbon
amino
acid
residu
fig
loss
hydrogen
bond
interact
could
reduc
inhibitori
activ
compound
k
mm
compar
activ
compound
k
mm
compound
k
mm
bear
unit
engag
two
fewer
hydrogen
bond
interact
amino
acid
residu
proteas
rel
shown
fig
studi
reveal
optim
posit
carbonyl
unit
indol
unit
import
achiev
potent
inhibitori
activ
order
evalu
indepth
bend
interact
potent
compound
sar
proteas
isotherm
titrat
calorimetri
studi
demonstr
fig
titrat
perform
c
inject
ml
aliquot
proteas
solut
calorimetr
cell
volum
w
ml
contain
inhibitor
concentr
mm
concentr
proteas
syring
mm
heat
evolv
upon
inject
proteas
obtain
integr
calorimetr
signal
heat
associ
inhibitor
bind
obtain
subtract
heat
dilut
heat
reaction
individu
heat
plot
molar
ratio
enthalpi
chang
dh
associ
constant
k
obtain
nonlinear
regress
data
bind
affin
compound
nm
good
agreement
k
valu
mm
describ
design
synthesi
biolog
evalu
seri
dipeptidetyp
inhibitor
novel
scaffold
sarscov
pro
dock
studi
involv
bind
dipeptid
lead
compound
pro
motiv
modif
flexibl
n
glycin
variou
structur
rigid
moieti
modif
led
identif
sever
potent
deriv
includ
display
inhibitori
activ
k
ic
submicromolar
nanomolar
rang
compound
particular
exhibit
potent
inhibitori
activ
k
valu
mm
respect
compound
attract
lead
develop
effort
toward
potent
peptidomimet
suitabl
pharmaceut
profil
sar
studi
around
site
lead
compound
led
identif
rigid
unit
one
best
moieti
optim
show
optim
methoxi
substitut
indol
unit
enhanc
inhibitori
activ
significantli
substitut
indol
also
found
import
inhibitori
potenc
sarscov
pro
reagent
solvent
purchas
wako
pure
chemic
ind
ltd
osaka
japan
aldrich
chemic
co
inc
milwauke
wi
use
without
purif
analyt
thin
layer
chromatographi
tlc
perform
merck
silica
gel
precoat
plate
prepar
hplc
perform
use
reversephas
column
mm
sunfir
prep
mm
binari
solvent
system
linear
gradient
ch
cn
aqueou
tfa
flow
rate
mlmin
compound
detect
nm
nm
solvent
use
hplc
hplcgrade
chemic
analyt
grade
better
h
c
nmr
spectra
obtain
use
jeol
mhz
spectromet
varian
mercuri
spectromet
mhz
bruker
spectromet
mhz
tetramethylsilan
intern
standard
chemic
shift
express
ppm
use
solvent
intern
standard
multipl
reson
peak
indic
singlet
broad
singlet
bs
doublet
triplet
quartet
q
multiplet
j
valu
given
hz
rel
number
proton
determin
integr
solvent
use
spectrum
report
highresolut
mass
spectra
esi
ei
record
micromass
qtof
ultima
api
jeol
jmsgcmate
spectromet
mass
spectra
esi
record
shimadzu
icecold
solut
methyl
g
mmol
dcm
ml
ad
bbr
ml
dcm
mmol
solut
stir
h
anoth
equival
ml
dcm
bbr
ad
stir
anoth
hour
mixtur
pour
crush
ice
ph
adjust
ad
solid
nahco
solut
extract
dcm
ml
dri
na
filter
evapor
reduc
pressur
give
carboxyl
acid
commerci
avail
dead
ml
mmol
slowli
ad
solut
acid
methyl
ester
g
mmol
triphenylphosphin
g
mmol
isopropanol
ml
mmol
ml
thf
stir
continu
min
solvent
evapor
crude
mixtur
purifi
chromatographi
give
pure
methyl
dissolv
ml
thf
solut
contain
lioh
h
mmol
thf
h
ad
mixtur
stir
overnight
c
solvent
evapor
residu
partit
water
etoac
water
layer
acidifi
nhcl
extract
twice
etoac
ml
combin
organ
layer
wash
brine
dri
na
filter
evapor
give
compound
synthes
isobutanol
use
method
similar
method
describ
prepar
solut
ethyl
g
mmol
anhydr
n
ndimethylformamid
ml
ad
dropwis
onto
icecool
solut
phosphoru
oxychlorid
ml
mmol
dmf
ml
reaction
mixtur
heat
c
h
cool
reaction
quench
ice
water
made
alkalin
addit
sodium
hydroxid
solut
precipit
collect
purifi
column
chromatographi
give
ethyl
g
mmol
ad
mixtur
acetyl
chlorid
ml
mmol
aluminum
chlorid
g
mmol
anhydr
ml
reaction
mixtur
heat
reflux
h
cool
reaction
mixtur
pour
crush
ice
made
acid
addit
n
hcl
mixtur
extract
dichloromethan
ml
combin
organ
layer
wash
brine
dri
evapor
residu
purifi
silica
gel
column
chromatographi
provid
mixtur
g
mmol
triethylsilan
g
mmol
acid
ml
stir
room
temperatur
h
quench
satur
solut
sodium
carbon
mixtur
extract
ethyl
acet
ml
combin
organ
layer
wash
satur
solut
sodium
bicarbon
brine
solut
dri
evapor
solvent
residu
purifi
column
chromatographi
give
ethyl
yield
yellow
solid
compound
synthes
use
procedur
similar
describ
prepar
yellow
solid
solut
ethyl
g
mmol
thf
ml
room
temperatur
ad
lioh
h
water
g
mmol
h
stir
solvent
complet
evapor
reduc
pressur
result
residu
neutral
n
hcl
solut
extract
etoac
ml
dri
na
filter
evapor
reduc
pressur
give
correspond
acid
yield
brown
solid
synthesi
achiev
use
procedur
similar
describ
prepar
yield
brown
mmol
result
solut
cool
c
ice
bath
condit
tea
ad
dropwis
min
ice
bath
remov
mixtur
allow
stir
h
ambient
temperatur
dmf
remov
high
vacuum
result
residu
dissolv
etoac
ml
organ
layer
wash
citric
acid
ml
nahco
ml
brine
ml
solut
dri
na
filter
evapor
reduc
pressur
give
compound
result
crude
compound
purifi
silica
gel
column
chromatographi
use
hexaneeetoac
eluent
tertbutyl
pentano
yield
acid
solut
correspond
tertbutyl
ester
mmol
ch
cl
ml
c
ad
tfah
ml
min
stir
reaction
mixtur
allow
stir
room
temperatur
h
solvent
complet
evapor
reduc
pressur
give
correspond
acid
directli
use
subsequ
step
without
character
solut
contain
acid
g
mmol
dmf
ml
ad
edc
hcl
g
mmol
hobt
h
g
mmol
n
odimethylhydroxylamin
g
mmol
room
temperatur
solut
cool
c
tea
ml
mmol
ad
slowli
h
dmf
evapor
result
residu
dissolv
ethyl
acet
ml
organ
phase
subsequ
wash
citric
acid
ml
nahco
ml
brine
ml
organ
layer
dri
na
concentr
reduc
pressur
yield
weinreb
amid
deriv
purifi
column
chromatographi
etoacmeoh
solut
benzothiazol
mmol
thf
ml
c
ad
nbuli
thf
ml
dropwis
min
h
stir
weinreb
amid
g
mmol
thf
ml
slowli
ad
min
solut
stir
h
reaction
quench
sat
nh
cl
allow
stir
c
min
mixtur
evapor
dissolv
etoac
ml
solut
wash
water
ml
brine
ml
dri
na
organ
layer
concentr
reduc
pressur
result
residu
subject
flash
chromatographi
etoac
meoh
obtain
pure
compound
character
data
compound
report
elsewher
solut
g
mmol
ch
cl
ml
c
ad
tfah
ml
solut
stir
h
evapor
solvent
reduc
pressur
correspond
deprotect
lactam
residu
g
mmol
coupl
carboxyl
acid
g
mmol
use
coupl
agent
hbtu
g
mmol
presenc
diisopropylethylamin
ml
mmol
dmf
ml
c
min
stir
ice
bath
remov
solut
allow
stir
h
ambient
condit
solvent
evapor
high
vacuum
residu
dissolv
ethyl
acet
ml
organ
layer
wash
citric
acid
ml
nahco
ml
brine
ml
solut
dri
na
filter
evapor
reduc
pressur
give
compound
yield
compound
synthes
use
procedur
similar
describ
prepar
crystal
structur
sarscov
pro
proteas
complex
substrat
analog
inhibitor
code
obtain
protein
data
bank
pdb
http
wwwrcsborg
pdbhomehomedo
initi
bind
model
pro
simul
form
basi
comparison
previou
lead
substrat
analog
use
molecular
oper
environ
moe
softwar
sever
minim
process
perform
use
forc
field
model
solvat
environ
surround
inhibitor
structur
rel
low
bind
free
energi
high
number
cluster
member
select
subsequ
dock
conform
optim
step
minim
energi
obtain
dock
studi
kcalmol
substrat
analog
remov
crystal
structur
dock
studi
perform
use
accord
method
similar
method
describ
dock
studi
bind
studi
isotherm
titrat
calorimetri
itc
use
vpitc
microcalorimet
microcalg
healthcar
northampton
usa
sarscov
pro
inhibitor
dissolv
buffer
compos
mm
sodium
phosphat
ph
mm
nacl
mm
tcep
mm
edta
dmso
titrat
perform
c
inject
ml
aliquot
proteas
solut
calorimetr
cell
volum
w
ml
contain
inhibitor
concentr
mm
concentr
proteas
syring
mm
heat
evolv
upon
inject
proteas
obtain
integr
calorimetr
signal
heat
associ
inhibitor
bind
obtain
subtract
heat
dilut
heat
reaction
individu
heat
plot
molar
ratio
enthalpi
chang
dh
associ
constant
k
obtain
nonlinear
regress
data
see
fig
